One of the state’s largest life science companies, gene therapy developer bluebird bio, says it plans to split into two separate companies, both located in the Boston-Cambridge area.
The company, now headquartered at 60 Binney St. in Kendall Square, with offices in Seattle and Durham, North Carolina, says it plans to spin out its cancer drugs now in development. The new company will initially be called Oncology Newco.
Bluebird Bio is a MLSC Tax Incentive Awardee, a program that authorizes tax incentives each year for growing companies engaged in life sciences research and development, commercialization and manufacturing. The primary goal of the program is to incentivize life sciences companies of all sizes to create new, long-term jobs in Massachusetts.